Navigation Links
Favrille to Host Conference Call and Live Webcast to Discuss Fourth Quarter and Year End 2007 Financial Results on February 19, 2008
Date:2/5/2008

SAN DIEGO, Feb. 5 /PRNewswire-FirstCall/ -- Favrille, Inc. (Nasdaq: FVRL), a biopharmaceutical company developing patient-specific, active immunotherapies for the treatment of cancer, announced today that it will host a conference call and live webcast at 5:00 p.m. Eastern Time on Tuesday, February 19, 2008 to discuss the Company's fourth quarter and year end 2007 financial results. A press release will be issued before the U.S. stock markets open that morning.

A live audio webcast of management's presentation will be available on the Investor Relations section of the Company's web site at http://www.favrille.com. Alternatively, callers may participate in the conference call by dialing (888) 713-4213 or (617) 213-4865, passcode 19388148. To pre-register for this call, please go to https://www.theconferencingservice.com/prereg/key.process?key=P9YHNKNHB. Callers who pre-register will be given a unique PIN to gain immediate access to the call and bypass the live operator. You may pre-register at any time, including up to and after the call start time. A telephone replay of the call will also be available for 48 hours. The telephone replay can be accessed by dialing (888) 286-8010 or (617) 801-6888, passcode 99385491.

About Favrille, Inc.

Favrille, Inc. is a biopharmaceutical company focused on the development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system. The Company's lead product candidate, Specifid(TM) (formerly FavId(R)), is based upon unique genetic information extracted from a patient's tumor. Specifid is currently under investigation in a pivotal Phase 3 clinical trial for patients with follicular B-cell non- Hodgkin's lymphoma (NHL) and Phase 2 clinical trials in other B-cell NHL indications. The Company is developing additional applications based on its immunotherapy expertise and proprietary cost-effective manufacturing technology, including a second product candidate, FAV-201, for the treatment of cutaneous T-cell lymphoma.

Company Contact:

Pete De Spain

Director, Investor Relations

& Corporate Communications

Favrille, Inc.

(858) 526-2426

pdespain@favrille.com


'/>"/>
SOURCE Favrille, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Favrille to Report New Data on FavId (Now Specifid) at American Society of Hematology Annual Meeting
2. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
3. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
4. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
5. GPhAs 2007 Annual Policy Conference Features Top Generic Industry CEOs; FDA, Government Officials; Wall Street Analysts
6. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
7. Omnicell to Present at Thomas Weisel Healthcare Conference 2007
8. AtriCure to Present at Roth Capital Partners 2007 New York Conference
9. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
10. MDS to Present at Thomas Weisel Partners Healthcare Conference
11. Hospira to Present at the Bear Stearns 20th Annual Healthcare Conference on September 11
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... ... 2016 , ... Sunny Isles Beach is in the Zone B floodplain where ... utility services. The time for planning is now, before a storm is approaching. , ... place. Families should follow the recommendations of the Miami-Dade County (MDC) Office of ...
(Date:5/31/2016)... ... May 31, 2016 , ... "ProDrop 3D Abstract will spark new ... level," said Christina Austin - CEO of Pixel Film Studios. , Create an ... Abstract have the ability to generate and manipulate three-dimensional shapes with ease all within ...
(Date:5/31/2016)... ... 2016 , ... Joe DiMaggio Children’s Hospital (JDCH) ... The clinic is led by a world class team of physicians, board certified ... also a team of certified vestibular therapists. , The Concussion Clinic operates ...
(Date:5/31/2016)... ... , ... According to recent statistics, there are nearly half a million ... Each physical therapy professional and every clinic has a duty to perform at ... in a competitive industry is also essential. The solution that many physical therapy leaders ...
(Date:5/31/2016)... ... May 31, 2016 , ... RF Safe's has decades of ... accessories to avoid excessive Smartphone radiation implicated in the most recent cell phone cancer ... bioRxiv preprint server on May 26th (PDF) by the National Toxicology Program ...
Breaking Medicine News(10 mins):
(Date:5/31/2016)... und GERMANTOWN, Maryland , ... Referenzdatensatz von Horizon bestätigt nachgewiesene Genauigkeit ... s   QIAGEN N.V. (NASDAQ: ... QIA) gab heute die Ergänzung seines GeneReader ... Verifizierungsdaten bekannt, die die bewährte Genauigkeit seines ...
(Date:5/31/2016)... , Germany and ... -- QIAGEN N.V. (NASDAQ: QGEN ... extensive package consisting of a quality control set and ... System, reinforcing the proven accuracy of its next-generation sequencing ... training for laboratories. QIAGEN has incorporated the Horizon Discovery ...
(Date:5/31/2016)... Mich. , May 31, 2016 Diplomat Pharmacy, ... "Diplomat Dialogue," a video conversation slated for June 7, 2016, ... event, hosted live from noon to 1 p.m. ET, will ... who helped him along the road to wellness. ... live conversations planned between patients and health care professionals, talking ...
Breaking Medicine Technology: